COMP <GO>
RVMD vs ABBV // FORWARD P/E MULTIPLE
Revolution Medicines Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: RVMD 3
— ABBV 7
▲ FORWARD P/E MULTIPLE LEADER: RVMD
LAST: $190.27 (+0.82%) • MKT CAP: $40.78B
forward-pe
34.0x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RVMD VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RVMD | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -28.60% | 29.00% | -57.60 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.24% | 3.47% | -5.71 | ABBV | /fcf-yield <GO> |
| Operating Margin | — | 24.60% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 6.90% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 15.40% | 8.60% | +6.80 | RVMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.33 | +20.67 | RVMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.8 | 65.1 | -17.30 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 1.15 | -0.08 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 34.0x | 113.1x | -79.10 | RVMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $40.78B | $513.86B | -$473.08B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RVMD REV | ABBV REV | RVMD GROSS % | ABBV GROSS % | RVMD FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $61.16B | — | 70.2% | -$913.7M | $17.82B |
| FY 2024 | $0 | $56.33B | — | 70.0% | -$567.7M | $17.83B |
| FY 2023 | $11.6M | $54.32B | — | — | -$351.1M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RVMD // BETA 1.07
ABBV // BETA 1.15